APA (7th ed.) Citation

S, Q., M, C., AL, C., AO, K., M, K., HC, L., . . . PKH, C. (2023). Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial. Lancet (London, England), 402(10415), 1835. https://doi.org/10.1016/S0140-6736(23)01796-8

Chicago Style (17th ed.) Citation

S, Qin, et al. "Atezolizumab Plus Bevacizumab Versus Active Surveillance in Patients with Resected or Ablated High-risk Hepatocellular Carcinoma (IMbrave050): A Randomised, Open-label, Multicentre, Phase 3 Trial." Lancet (London, England) 402, no. 10415 (2023): 1835. https://doi.org/10.1016/S0140-6736(23)01796-8.

MLA (9th ed.) Citation

S, Qin, et al. "Atezolizumab Plus Bevacizumab Versus Active Surveillance in Patients with Resected or Ablated High-risk Hepatocellular Carcinoma (IMbrave050): A Randomised, Open-label, Multicentre, Phase 3 Trial." Lancet (London, England), vol. 402, no. 10415, 2023, p. 1835, https://doi.org/10.1016/S0140-6736(23)01796-8.